---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-004591"
form_type: "8-K"
ticker: "KPTI"
cik: "0001503802"
company_name: "Karyopharm Therapeutics Inc."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:09:30.168288+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Karyopharm estimates FY2024 total rev ~$145M; Phase 3 MF data in 2H 2025

## Summary
- Preliminary FY2024 total revenue ~$145M, XPOVIO net product rev ~$113M; Q4 rev ~$30M, XPOVIO ~$29M.
- Phase 3 SENTRY trial (selinexor+ruxolitinib in MF) enrollment completion in 1H 2025, top-line data in 2H 2025.
- Appointed Lori Macomber as CFO (Jan 3, 2025) and Brendan Strong as SVP IR (Dec 9, 2024).
- Cash, equivalents, and investments ~$109M as of Dec 31, 2024; expected runway into Q1 2026 (excl. note repayment).

## SEC filing metadata
- accession: 0000950170-25-004591
- form_type: 8-K
- ticker: KPTI
- cik: 0001503802
- company_name: Karyopharm Therapeutics Inc.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1503802/000095017025004591/0000950170-25-004591-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1503802/000095017025004591/kpti-20250113.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-004591
- JSON: https://secwatch.observer/filing/0000950170-25-004591.json
- Plain text: https://secwatch.observer/filing/0000950170-25-004591.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.